Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

ICA Gruppen issues green bonds

ICA Gruppen has successfully completed a green bond issue of SEK 3.5 billion under the company’s Swedish MTN programme.The issue saw strong demand and was more than 1.5 times oversubscribed. The bonds of SEK 1.25 billion and SEK 2.25 billion were issued with tenors of 3 and 5 years respectively, both tenors with fixed and floating rate tranches. This represents ICA Gruppen’s first green bond issue, following the company's recently established Green Finance Framework, developed to align with the ICMA Green Bond Principles. CICERO Shades of Green, now part of S&P Global, has provided a

Investor’s Head of Corporate Communication & Sustainability Viveka Hirdman-Ryrberg steps down

Viveka Hirdman-Ryrberg, age 60, has decided to step down after close to five years at Investor and more than 30 years within the Wallenberg sphere.“Viveka has been instrumental in setting and driving our sustainability strategy as well as gearing up our communication work. She is a true change agent that gets things done and has been a much-appreciated colleague. While highly regrettable, I have full respect for her decision and wish her all the best going forward,” says Johan Forssell, Investor’s President and CEO.“It has been a great privilege to be a part of the fantastic Investor

DDM Holding AG and DDM Debt AB to report first quarter 2023

DDM Holding AG (First North Growth Market: DDM) and its subsidiary DDM Debt AB (Nasdaq Stockholm: DDM Debt 2026) will publish their Q1 2023 reports on Tuesday 30 May 2023 at 08:00 CEST. Dr. Andreas Tuczka, Executive Chairman, and Mr. Fredrik Olsson, CFO, will host a conference call the same day, beginning at 10:00 CEST, to present and comment on the DDM Group’s financial results. The conference will be held in English and can be followed live on www.ddm-group.ch  or via teleconference with prior registration at: https://

DDM Holding AG and DDM Debt AB to report first quarter 2023

DDM Holding AG (First North Growth Market: DDM) and its subsidiary DDM Debt AB (Nasdaq Stockholm: DDM Debt 2026) will publish their Q1 2023 reports on Tuesday 30 May 2023 at 08:00 CEST. Dr. Andreas Tuczka, Executive Chairman, and Mr. Fredrik Olsson, CFO, will host a conference call the same day, beginning at 10:00 CEST, to present and comment on the DDM Group’s financial results. The conference will be held in English and can be followed live on www.ddm-group.ch  or via teleconference with prior registration at: https://

Valmet signs a service agreement with UBE Corporation in Spain

Valmet Oyj’s trade press release on May 16, 2023 at 9:30 a.m. EESTValmet and UBE Corporation Europe S.A.U. have signed a service agreement to improve the waste boiler’s performance at UBE’s chemical plant in Castellón, Spain. The agreement was included in Valmet's orders received of the first quarter 2023 and was effective immediately. The value of the agreement will not be disclosed. Through the service agreement UBE is expecting to utilize Valmet’s support in optimizing the boiler’s availability and performance as well as developing the inspection and maintenance practices further.

Cline Scientific announces Letter of Intent with NecstGen for the manufacture of its stem cell therapy for damaged cartilage

Mölndal, Sweden and Leiden Netherlands, - Cline Scientific, a Swedish life science company developing a novel regenerative medicine, and NecstGen, a CDMO and centre of excellence for Cell and Gene Therapy, have signed a Letter of Intent to develop and manufacture clinical batches of Cline’s cell therapy for cartilage repair, StemCART.Through this intended partnership, NecstGen will support the further development and manufacture of Cline’s cell therapy for damaged cartilage, StemCART. StemCART is an Advanced Therapy Medicinal Product (ATMP) that aims to revolutionize the treatment of

ExpreS2ion announces financial results for the first quarter 2023

Hørsholm, Denmark, 16 May 2023– ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its first quarter financial results for 2023. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments “In the first quarter of 2023, we made significant progress and secured additional funding for our pipeline-driven strategy, while also strengthening our organisation and improving access to valuable scientific knowledge in the field of infectious diseases. Overall, our outlook for the

Tobii collaborates with Automotive Motion Lab in a research project to detect driver drowsiness without cameras

Tobii, the world leader in eye tracking and pioneer in attention computing, and Automotive Motion Lab, a joint initiative by Stellantis and Aix-Marseille Université, are collaborating to evaluate driver drowsiness from several physiological measurements and seat data. The initiative is another testament to Tobii´s commitment to making roads safer with innovative technology.    Today, the driver monitoring systems (DMS) on the market are primarily built on camera-based analysis of the driver’s face and eyes and/or driving behavior, such as lane deviation or steering behavior. Tobii and

Kamux Oyj - Managers' Transactions

Kamux Corporation, Managers’ Transactions, 16.5.2023 at 9:15 Kamux Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Marko Lehtonen Position: Chief Financial Officer Issuer: Kamux Oyj LEI: 743700KCVYIYNLPZYN56 Notification type: INITIAL NOTIFICATION Reference number: 31768/5/4 ____________________________________________ Transaction date: 2023-05-15 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000206750 Nature of transaction: ACQUISITION

Eevia Health Plc receives a 459 KSEK / 41 KEUR sales order for a bilberry extract

Eevia Health Plc, (”Eevia” or ”The Company”), has received a sales order from a European customer of c. 41 KEUR for an organically certified bilberry extract.Following a successful exhibit at the international nutraceutical tradeshow Vitafoods in Geneva Switzerland, Eevia received a new order for a bilberry extract. The European customer is a local brand with nutritional supplements in several countries in central Europe. The Customer has a focus on eye health, a professional approach to quality, and a strong presence in the market. The sales value to Eevia of this new order is c. KEUR

Eevia Health Plc Interim Report Q1 - 2023

Eevia Health Plc ("Eevia" or "The Company") is releasing its quarterly financial report for the first quarter of 2023. Summary of the first quarter 2023 (Q1-23):· Net sales1 grew by 20% from KEUR 1 420 in Q4-22 to KEUR 1 710 in Q1-23. Net sales between Q1-22 and Q1-23 grew by 6% (from KEUR 1 617 in Q1-22 to KEUR 1 710 in Q1-23) when excluding revenue of KEUR 42 from tradingof raw materials in Q1-22. · The gross profit in Q1-23 landed at KEUR 989, an improvement of 362% from KEUR 214 in Q1-22. The gross margin2 was 58%, up from 13% in Q1-22. The increase is due to the improvements

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023

First quarter (January-March 2023) · Operating profit/loss totaled SEK -2,265,857 (-4,741,051). · Loss for the period totaled SEK -2,266,329 (-4,754,615). · Cash flow from operating activities totaled SEK -2,035,828 (-5,333,226). · Earnings per share before dilution totaled SEK -0.11 (-0,24). Earnings per share after dilution amounted to SEK - 0.11 (-0,24).   Key events during the first quarter · Elicera continues Phase I/IIa trial with oncolytic virus as planned, following safety review in cohort 3. · Elicera submits Clinical Trial Application to evaluate its

Askel Healthcare to raise 5 million euros for clinical research of its COPLA® -implant to treat knee pain caused by cartilage damage

Askel Healthcare, the Finnish medical technology company offering a new method for the treatment of knee cartilage damage, has started a fundraising campaign to raise up to 5 million euros to finance clinical trials of its COPLA[®] implant. The public phase of the ongoing fundraising campaign started today and closes on 18 June 2023. An investor meeting will take place on 24 May 2023 at 16:00 EEST at VALO Hotel & Work and online. Askel Healthcare’s COPLA[®] implant is a new biodegradable implant for the surgical treatment of cartilage damage in the knee. Askel Healthcare is targeting the

Interim Report for 1st Quarter 2023

Revenues increased 20% and EBIT increased 260%Key Facts for the 1[st] Quarter 2023 (1[st] January – 31[st] March 2023) Revenues increased 20% and EBIT increased 260% All figures are compared to the same quarter last year if not explicitly stated otherwise. · Revenues increased by 20.12 % to €9,428,231 (€7,848,997). · EBIT increased by 259.97% to €1,501,926 (€417,239). · EBIT margin of 15.93% (5.32%). · Customer deposits increased by 2.10% to €17,599,353 (€17,236,925). · 53,408 new registered customers (74,751), decrease of 28.55%. · 11,508 new depositing customers (

Esmaeilzadeh Holding publishes net asset value as of 30 April 2023

As of 30 April 2023, the net asset value for Esmaeilzadeh Holding AB (publ) was SEK 7.57 billion (SEK 7.59 billion as of 31 March 2023), corresponding to a net asset value per share of SEK 9,818 (SEK 9,848 as of 31 March 2023). For further information, please contact: Saeid Esmaeilzadeh, CEO and founder +46 707 18 70 61, saeid@ehab.group Nils Fredrik Lagerstrand, General Counsel & Deputy CEO +46 720 90 26 99, nilsfredrik@ehab.group The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CEST on 16 May 2023. About

Two additional ClearPoint™ Prism systems installed in the U.S.

Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announces that its global distributor within neurosurgery ClearPoint Neuro Inc. installed two additional ClearPoint Prism™ Neuro Laser Therapy Systems in the U.S. In total, there are now three of the company’s system for MR-guided laser ablation installed on the American neurosurgery market.CLS’s global distributor ClearPoint Neuro Inc, continues the limited market release in the U.S. of ClearPoint Prism Neuro Laser Therapy System, which is the new brand name for the laser ablation system for MR-guided

Interim Report January-March 2023

Record earnings and strong growth in all areas of the business January-March 2023 · Net sales totaled SEK 71,276 (32,574) thousand, with a growth rate of 119%. Growth is 107%, adjusted for currency effects. Net sales include USD 4 million in license revenues from Selecta Biosciences. Organic growth adjusted for license revenues from Selecta Biosciences is 41%, and 30% when also adjusted for currency effects.  · Gross profit totaled SEK 67,098 (29,419) thousand. · Operating profit before depreciation and amortization (EBITDA) totaled SEK 45,089 (11,717) thousand. · Operating

Fazer to begin pilot sales of unique grain-based Fazer Taste the Future candy tablets with no cocoa

Fazer actively monitors shifting consumer trends and requirements and drives the development of the food industry. Introducing innovative and sustainable food solutions is one of Fazer’s priorities, and to this end, Fazer launches a unique vegan candy tablet, Taste the Future, produced without cocoa. The novelty candy tablet is produced with malted Finnish grain and comes in two different flavours. It will be available as limited edition at selected Fazer Retail outlets from 16 May 2023. The exciting innovation is a part of Fazer’s agenda for developing the future of chocolate.Consumers are

MPCC: Invitation to Q1 2023 Earnings Call

MPC Container Ships ASA will publish its Q1 2023 financial report on Tuesday, May 23, 2023. Constantin Baack, CEO, and Moritz Fuhrman, CFO, will present the results in an earnings call at 15:00 CEST / 09:00 EST on May 23, 2023, followed by a  Q&A session. The earnings call can be accessed live via webcast or conference call and questions can be submitted orally or in writing. A recording of the earnings call will be available on demand at the Company's website after the live event has concluded. The live webcast can be accessed through the following link: https://edge.media-server.com/

Q1 Report – 31 March 2023

Flexion reports continued strong growth. Quarterly revenue grows by 54% and adjusted EBITDA up by 125%.January-March 2023 performance · Total revenue increased by 54% to GBP 16.3m (10.6)* · Gross profit increased by 72% to GBP 2.5m (1.5) · Adjusted EBITDA[‡] increased by 125% to GBP 0.7m (0.3) · Adjusted loss before tax[#] amounted to GBP -0.1m (0.1) · EPS amounted to GBP -0.97 pence (0.51 pence) · Adjusted EPS amounted to GBP -0.28 pence (0.19 pence) · Operating cash flow amounted to GBP -1.1m (1.9) · Cash and cash equivalents amounted to GBP 12.0m (10.4)

Implantica announces that RefluxStop™ results were presented at the DDW Conference in Chicago

Implantica AG (publ), a medtech company at the forefront of bringing advanced technology into the body, announces that Dr. med. Zehetner, Prof. (USC) from Switzerland, presented Klinik Beau-Site’s RefluxStop™ results at Digestive Disease Week (DDW) 6-9 May, in Chicago, U.S., the world’s premier meeting for gastrointestinal professionalsDr. med. Jörg Zehetner, Prof. (USC), surgeon at the Hirslanden Klinik Beau-Site Bern, Switzerland, highlighted the unique advantages of the RefluxStop™ therapy in the reflux patient population that have Ineffective Esophageal Motility (IEM), a disorder that

KLAR Partners boosts Enerim’s future growth prospects through a strategic divestment of its Wholesale Markets business to allow enhanced focus on its market-leading SaaS solutions

After a successful carve-out and reorganisation of the business, funds advised by KLAR Partners Limited (“KLAR Partners” or “KLAR”) are supporting Enerim Oy (“Enerim” or the “Company”) on the next step of its growth journey. By divesting its Wholesale Markets business, the company can concentrate on streamlining its software offering while consolidating its leading position as a supplier of SaaS solutions to utility companies in northern Europe.With its End User Markets business, Enerim has established itself as a market-leading provider of mission-critical SaaS solutions that automate

Proact subsidiary Conoa partners with Isovalent

Proact and its subsidiary Conoa – a Kubernetes, cloud native and container technology consulting firm has entered into a partnership with Isovalent to further expand its portfolio around visibility, control, performance, and security of customers’ container environments.As the first Isovalent  partner in Sweden, Conoa is authorised to resell and implement Isovalent Cilium Enterprise – an innovative technology that offers efficient and scalable network connectivity and security for Kubernetes-based container environments. Conoa can support customers across all Proact

There are no items matching the current filter
There are no more items matching the current filter
Back to top